Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

Recent & Breaking News (NEO:CYBN)

Cybin to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis

Business Wire March 10, 2021

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

Business Wire March 9, 2021

Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021

Business Wire March 8, 2021

Cybin Inc. Announces Uplisting to OTCQB Venture Market

Business Wire March 3, 2021

Cybin Announces Closing of Upsized Bought Deal Offering

Business Wire February 4, 2021

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Canadian Press, with file by Stockhouse January 11, 2021

CYBIN Provides Update on Patent Filings & Development of Therapeutics Program

Business Wire January 6, 2021

CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings

GlobeNewswire December 14, 2020

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth

Canadian Press, with file by Stockhouse December 7, 2020

Psychedelics Leader Cybin Inc. Completes RTO and is Now Trading on the NEO

Dave Jackson November 11, 2020

Cybin Goes Public on NEO Exchange

Business Wire November 10, 2020

Cybin Completes Reverse Take-Over Transaction. Common Shares Expected to Commence Trading on the NEO Exchange on or about November 10, 2020

Canadian Press, with file by Stockhouse November 5, 2020

CYBIN and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTO

Canadian Press, with file by Stockhouse October 19, 2020

Opening the Door to the New Psychedelics Revolution

Dave Jackson October 9, 2020

The StockTalk Cannabis Report: Oct. 9, 2020

Dave Jackson October 9, 2020

This Company Illustrates Exactly Why the Psilocybin Market is Exploding

Dave Jackson September 29, 2020

The StockTalk Cannabis Report: Sept. 25, 2020

Dave Jackson September 25, 2020

Cybin Corp Announces Doug Drysdale as Chief Executive Officer

Canadian Press, with file by Stockhouse September 1, 2020

Cybin Applauds TheraPsil’s Advocacy to Bring Psilocybin Therapy to Palliative Care of Canadian Patients

Canadian Press, with file by Stockhouse August 7, 2020

IntelGenx and Cybin Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

GlobeNewswire July 7, 2020